Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

Sarepta Therapeutics to Present Company Overview at Upcoming Conferences

ID: 318099

Webcast Accessible via Sarepta Therapeutics Website


(firmenpresse) - CAMBRIDGE, MA -- (Marketwired) -- 11/19/13 -- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-based therapeutics, announced today that it is scheduled to present at the following investor conferences in December. Chris Garabedian, Sarepta's president and chief executive officer, will be the presenter.

Deutsche Bank BioFEST in Boston, MA on Monday, December 2, 2013 at 5:10 p.m. Eastern Time.

Piper Jaffray 25th Annual Healthcare Conference in New York, NY on Wednesday, December 4, 2013 at 9:30 a.m. Eastern Time.

The presentations will be webcast live on the investor relations section of the Sarepta Therapeutics website at and will be archived under the events and presentations section following the presentation for 90 days. Please connect to Sarepta's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.



Sarepta Therapeutics is focused on developing first-in-class RNA-based therapeutics to improve and save the lives of people affected by serious and life-threatening rare and infectious diseases. The Company's diverse pipeline includes its lead program eteplirsen, for Duchenne muscular dystrophy, as well as potential treatments for some of the world's most lethal infectious diseases. Sarepta aims to build a leading, independent biotech company dedicated to translating its RNA-based science into transformational therapeutics for patients who face significant unmet medical needs. For more information, please visit us at .



Sarepta Investor Contact:
Erin Cox
857.242.3714


Sarepta Media Contact:
Jim Baker
857.242.3710



Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
drucken  als PDF  an Freund senden  ProMetic Receives $5.1 Million Purchase Order from Multinational Client Q Therapeutics Receives Orphan Drug Designation From U.S. Food & Drug Administration for Q-Cells(R) for Treatment of ALS
Bereitgestellt von Benutzer: Marketwired
Datum: 19.11.2013 - 13:30 Uhr
Sprache: Deutsch
News-ID 318099
Anzahl Zeichen: 0

contact information:
Town:

CAMBRIDGE, MA



Kategorie:

Biotech



Diese Pressemitteilung wurde bisher 345 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Sarepta Therapeutics to Present Company Overview at Upcoming Conferences"
steht unter der journalistisch-redaktionellen Verantwortung von

Sarepta Therapeutics, Inc. (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Sarepta Therapeutics, Inc.



 

Werbung



Facebook

Sponsoren

foodir.org The food directory für Deutschland
Informationen für Feinsnacker finden Sie hier.

Firmenverzeichniss

Firmen die firmenpresse für ihre Pressearbeit erfolgreich nutzen
1 2 3 4 5 6 7 8 9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z